نتائج البحث - "Daniil, Stroyakovskiy"

1

Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma

المساهمون: HUS Comprehensive Cancer Center, Clinicum, Department of Oncology

المصدر: Eggermont, A MM, Meshcheryakov, A, Atkinson, V, Blank, C U, Mandala, M, Long, G V, Barrow, C, Di Giacomo, A M, Fisher, R, Sandhu, S, Kudchadkar, R, Ortiz Romero, P L, Svane, I M, Larkin, J, Puig, S, Hersey, P, Quaglino, P, Queirolo, P, Stroyakovskiy, D, Bastholt, L, Mohr, P, Hernberg, M, Chiarion-Sileni, V, Strother, M, Hauschild, A, Yamazaki, N, van Akkooi, A CJ, Lorigan, P, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2021, ' Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma ', European Journal of Cancer, vol. 158, pp. 156-168 . https://doi.org/10.1016/j.ejca.2021.09.023Test
Eggermont, A M, Meshcheryakov, A, Atkinson, V, Blank, C U, Mandala, M, Long, G V, Barrow, C, Di Giacomo, A M, Fisher, R, Sandhu, S, Kudchadkar, R, Ortiz Romero, P L, Svane, I M, Larkin, J, Puig, S, Hersey, P, Quaglino, P, Queirolo, P, Stroyakovskiy, D, Bastholt, L, Mohr, P, Hernberg, M, Chiarion-Sileni, V, Strother, M, Hauschild, A, Yamazaki, N, van Akkooi, A C, Lorigan, P, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2021, ' Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma ', European journal of cancer (Oxford, England : 1990), vol. 158, pp. 156-168 . https://doi.org/10.1016/j.ejca.2021.09.023Test
Eggermont, A M M, Meshcheryakov, A, Atkinson, V, Blank, C U, Mandala, M, Long, G V, Barrow, C, Di Giacomo, A M, Fisher, R, Sandhu, S, Kudchadkar, R, Romero, P L O, Svane, I M, Larkin, J, Puig, S, Hersey, P, Quaglino, P, Queirolo, P, Stroyakovskiy, D, Bastholt, L, Mohr, P, Hernberg, M, Chiarion-Sileni, V, Strother, M, Hauschild, A, Yamazaki, N, van Akkooi, A C, Lorigan, P, Krepler, C, Ibrahim, N, Marreaud, S, Kicinski, M, Suciu, S & Robert, C 2021, ' Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma ', European Journal of Cancer, vol. 158, pp. 156-168 . https://doi.org/10.1016/j.ejca.2021.09.023Test

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::206bf54251ce7ab0bcaf3dc33467c927Test
https://findresearcher.sdu.dk:8443/ws/files/194774299/PIIS0959804921006201.pdfTest

2

Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 37, iss 25
Journal of Clinical Oncology

مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, Receptor, ErbB-2, medicine.medical_treatment, Docetaxel, Kaplan-Meier Estimate, Ado-Trastuzumab Emtansine, Carboplatin, chemistry.chemical_compound, ErbB-2, 0302 clinical medicine, Trastuzumab, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Medicine, Humanized, Adjuvant, Neoadjuvant therapy, Middle Aged, Neoadjuvant Therapy, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Female, Pertuzumab, RAPID COMMUNICATION, Receptor, medicine.drug, Adult, medicine.medical_specialty, Clinical Sciences, Oncology and Carcinogenesis, Breast Neoplasms, Antibodies, Monoclonal, Humanized, Antibodies, Disease-Free Survival, 03 medical and health sciences, Breast cancer, Internal medicine, Breast Cancer, Chemotherapy, Humans, Oncology & Carcinogenesis, Aged, business.industry, medicine.disease, 030104 developmental biology, chemistry, Trastuzumab emtansine, business

وصف الملف: Print-Electronic; application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::108221c07fe98c1622828a09784f0ec6Test
https://doi.org/10.1200/jco.19.00882Test

3

Real-World Experience with Targeted Therapy in BRAF Mutant Advanced Melanoma Patients: Results from a Multicenter Retrospective Observational Study Advanced Melanoma in Russia (Experience) (ADMIRE)

المصدر: Cancers, Vol 13, Iss 2529, p 2529 (2021)
Cancers
Volume 13
Issue 11

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6921260489f81e5cf67d124a56e8ccecTest
https://www.mdpi.com/2072-6694/13/11/2529Test

4

EFFICACY OF NIVOLUMAB (NWO) DURING 2+ LINE TREATMENT AND QUALITY OF LIFE IN PATIENTS WITH ADVANCED REFRACTORY NON-SMALL CELL LUNG CANCER: INTERIM RESULTS OF PROSPECTIVE OBSERVATIONAL STUDY

المصدر: Problems in oncology. 65:99-105

مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, business.industry, medicine.disease, Refractory, Quality of life, Internal medicine, Interim, medicine, Observational study, In patient, Nivolumab, Line (text file), business, Lung cancer

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::67e6f03b588762f53c9611345123f62aTest
https://doi.org/10.37469/0507-3758-2019-65-1-99-105Test

5

448P Efficacy of combinations of BRAF inhibitors and anti-EGFR antibodies in metastatic colorectal carcinoma (mCRC) patients with mBRAF in the real clinical practice

المصدر: Annals of Oncology. 32:S557-S558

مصطلحات موضوعية: Oncology, medicine.medical_specialty, biology, Colorectal cancer, business.industry, Hematology, medicine.disease, Clinical Practice, Internal medicine, medicine, biology.protein, Antibody, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::ef49574d91e907cbb2513b2cce5cf7a6Test
https://doi.org/10.1016/j.annonc.2021.08.969Test

6

Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial

المصدر: Sweeney, C, Bracarda, S, Sternberg, C N, Chi, K N, Olmos, D, Sandhu, S, Massard, C, Matsubara, N, Alekseev, B, Parnis, F, Atduev, V, Buchschacher, G L, Gafanov, R, Corrales, L, Borre, M, Stroyakovskiy, D, Alves, G V, Bournakis, E, Puente, J, Harle-Yge, M L, Gallo, J, Chen, G, Hanover, J, Wongchenko, M J, Garcia, J & de Bono, J S 2021, ' Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150) : a multicentre, randomised, double-blind, phase 3 trial ', The Lancet, vol. 398, no. 10295, pp. 131-142 . https://doi.org/10.1016/S0140-6736Test(21)00580-8

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ed49d978b85e5e5b25c9832cd16319eTest
https://pubmed.ncbi.nlm.nih.gov/34246347Test

7

Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study

المساهمون: Oncology, CCA - Cancer Treatment and Quality of Life, CCA -Cancer Center Amsterdam, Institut Català de la Salut, [Van Cutsem E] University Hospitals Leuven and KU Leuven, Leuven, Belgium. [Danielewicz I] Szpitale Wojewodzkie w Gdyni/Gdansk Medical University, Gdynia, Poland. [Saunders MP] Christie Hospital NHS Foundation Trust, Manchester, UK. [Pfeiffer P] Odense University Hospital, Odense, Denmark. [Argilés G] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Borg C] University Hospital Besançon, Besançon, France, Vall d'Hebron Barcelona Hospital Campus

المصدر: Annals of oncology, 31(9), 1160-1168. Oxford University Press
Scientia
Van Cutsem, E, Danielewicz, I, Saunders, M P, Pfeiffer, P, Argilés, G, Borg, C, Glynne-Jones, R, Punt, C J A, Van de Wouw, A J, Fedyanin, M, Stroyakovskiy, D, Kroening, H, Garcia-Alfonso, P, Wasan, H, Falcone, A, Kanehisa, A, Egorov, A, Aubel, P, Amellal, N & Moiseenko, V 2020, ' Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy : the randomized TASCO1 study ', Annals of Oncology, vol. 31, no. 9, pp. 1160-1168 . https://doi.org/10.1016/j.annonc.2020.05.024Test

مصطلحات موضوعية: 0301 basic medicine, Pyrrolidines, Medicaments antineoplàstics - Ús terapèutic, Phases of clinical research, Gastroenterology, Recte - Càncer - Quimioteràpia, trifluridine/tipiracil, Trifluridine, chemistry.chemical_compound, 0302 clinical medicine, Quality of life, intensive therapy, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, capecitabine, metastatic colorectal cancer, terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Trifluridine/tipiracil, Hematology, neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales [ENFERMEDADES], Bevacizumab, Oncology, 030220 oncology & carcinogenesis, Fluorouracil, Colorectal Neoplasms, medicine.drug, medicine.medical_specialty, TASCO1 study, bevacizumab, Neutropenia, Capecitabine, 03 medical and health sciences, Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms [DISEASES], Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Internal medicine, medicine, Humans, Tipiracil, business.industry, medicine.disease, Clinical trial, 030104 developmental biology, chemistry, Quality of Life, business, Thymine, Còlon - Càncer - Quimioteràpia